Immunomodulators (JAK inhibitors)
- Oral inhibitors of JAK-STAT cytokine signaling
- Treat RA, dermatitis, IBD + other diseases
- Fast and potent but systemically immunomodulatory
- Serious infection/zoster risk is important
- Thrombosis/MACE/malignancy warnings matter
- Drug selectivity does not eliminate class risk
Class at a glance
- Oral inhibitors of JAK-STAT cytokine signaling
Clinical role
- Treat RA, dermatitis, IBD + other diseases
- Fast and potent but systemically immunomodulatory
Safety / monitoring
- Serious infection/zoster risk is important
Safety distinctions
- Thrombosis/MACE/malignancy warnings matter
- Drug selectivity does not eliminate class risk
Pearls
- Atopic dermatitis: match dupilumab at usual doses, exceed at higher
- Itch relief can begin within a week
- Raise lipids; check a lipid panel
Drugs in this class (6)
Immunomodulators (JAK inhibitors) prescription history
Animated chart of estimated U.S. prescriptions per year, Tyrosine kinase inhibitors (2001–2026). JAK / TYK2 inhibitors highlighted from 2011.
All drug classes · Open Immunomodulators (JAK inhibitors) in the interactive console ↗